GlassScriptPhysician profile
Katherine A Davis
NPI 1649731977
$778.92
in general payments reported to CMS, 2019-2025
14 companies · $439 in 2025
The $439 reported for 2025 was more than what 92% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $30.83 · 2023: $71.55 · 2024: $238 · 2025: $439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $748.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $748.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $211.21 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Globus Medical, INC. | $108.29 | 2025 | Senza |
| Exact Sciences Corporation | $98.03 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $74.12 | 2024-2025 | Gardasil 9, Vaxneuvance, Gardasil |
| Glaxosmithkline, LLC. | $50.40 | 2024-2025 | Bexsero |
| Otsuka America Pharmaceutical, INC. | $49.22 | 2024-2025 | Rexulti |
| Pfizer INC. | $40.24 | 2024-2025 | |
| Sanofi Pasteur INC. | $37.30 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $30.83 | 2022 | |
| Novartis Pharmaceuticals Corporation | $19.30 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $18.40 | 2025 | Breztri |
| Astellas Pharma US INC | $14.25 | 2025 | Veozah |
| Mylan Specialty L.P. | $14.05 | 2023 | Yupelri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.28 | 2024 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.